Siglec-6
Siglec-6 Molekülinformation
| Englischer Name | Sialic acid-binding Ig-like lectin 6 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 2 | Target-Alias | CD33 antigen-like 1，CDw327，Obesity-binding protein 1 (OB-BP1)，OBBP1，CD33L，CD33L1，CD327 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Sialic acid-binding Ig-like lectin 6 |
| Target-Alias | CD33 antigen-like 1，CDw327，Obesity-binding protein 1 (OB-BP1)，OBBP1，CD33L，CD33L1，CD327 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 2 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
Siglec-6 Produktliste
- Attribut
Protein (1)
- Produktbibliothek
Online (1)
- Spezies
Human (1)
- Etikett
Fc Tag (1)
- Marker
Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human Siglec-6 / CD327 Protein, Fc Tag, low endotoxin |  |  |  |  In den Warenkorb legen |
Gesamtmenge1
- 1
Siglec-6 Molekülhintergrund
Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is also known as CD antigen CD327, CD33 antigen-like 1 (CD33L or CD33L1), Obesity-binding protein 1 (OB-BP1). SIGLEC6 belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family, which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. SIGLEC6 mediates sialic-acid dependent binding to cells. SIGLEC6 binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.
Siglec-6 Molekülalias
SIGLEC6,CD327,CD33L,CD33L1,OBBP1,OB-BP1,CDw327
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Leukemia, Myeloid, Acute | Details | |
| AK-006 | AK006 | Phase 1 Clinical | Allakos Inc | Chronic Urticaria; Inflammation | Details |
Produktrezensionen
C***u2022-06-25
0Menschen mögenThe item was expedited very quickly which worked out with our timeline. We are in the process of using the Siglec-6 protein in one of our in-vivo study for immunization. The material itself did not dissolve in complete freund's adjuvant but it was easily made into a fine suspension with the help of some PBS. Overall, I would say the material is easy to work with and the Acro is quick at responding if we have any issues.
- Molekülinformation
- Produktliste
- Produktrezensionen
- Klinische Arzneimittelinformation